The risk of determining risk with multivariable models

J Concato, AR Feinstein, TR Holford - Annals of internal medicine, 1993 - acpjournals.org
Purpose: To review the principles of multivariable analysis and to examine the application of
multivariable statistical methods in general medical literature. Data Sources: A computer …

Clinical applications of serum tumor markers

SE Bates - Annals of internal medicine, 1991 - acpjournals.org
▪ The pursuit of the ideal tumor marker has generated many tests for use in the diagnosis
and management of cancer, several of which are now widely available. Tumor markers have …

Guidelines on testicular cancer: 2015 update

P Albers, W Albrecht, F Algaba, C Bokemeyer… - European urology, 2015 - Elsevier
Context This is an update of the previous European Association of Urology testis cancer
guidelines published in 2011, which included major changes in the diagnosis and treatment …

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian …

CM Sturgeon, MJ Duffy, UH Stenman, H Lilja… - 2008 - academic.oup.com
Abstract Background: Updated National Academy of Clinical Biochemistry (NACB)
Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been …

Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort

G Daugaard, MG Gundgaard, MS Mortensen… - Journal of Clinical …, 2014 - ascopubs.org
Purpose To describe treatment results in a large cohort with stage I nonseminoma germ cell
cancer (NSGCC) treated in a surveillance program. Patients and Methods From January 1 …

Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant …

P Albers, R Siener, S Krege, HU Schmelz… - Journal of Clinical …, 2008 - ascopubs.org
Purpose Retroperitoneal lymph node dissection (RPLND) and adjuvant chemotherapy are
two adjuvant treatment options for patients with clinical stage I nonseminomatous germ cell …

Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party.

G Read, SP Stenning, MH Cullen… - Journal of clinical …, 1992 - ascopubs.org
PURPOSE A prospective study of surveillance after orchidectomy alone in patients with
stage I nonseminomatous germ cell testicular tumor (NSGCT) was performed to determine …

Late relapse of testicular cancer.

J Baniel, RS Foster, R Gonin, JE Messemer… - Journal of clinical …, 1995 - ascopubs.org
PURPOSE This study analyzed a large group of patients with testicular germ cell cancer in
complete remission, who relapsed more than 2 years after completion of treatment …

Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program

T Tandstad, O Dahl, G Cohn-Cedermark… - Journal of clinical …, 2009 - ascopubs.org
Purpose To offer minimized risk-adapted adjuvant treatment on a nationwide basis for
patients with clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) …

Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.

MH Cullen, SP Stenning, MC Parkinson… - Journal of clinical …, 1996 - ascopubs.org
PURPOSE This United Kingdom Medical Research Council (UK-MRC) study prospectively
evaluated efficacy and long-term toxicity of adjuvant chemotherapy in high-risk stage I …